Topic
SEC filings
2 articles
IPO pricing
Retension Pharmaceuticals Files 424B4 Prospectus for IPO
Retension Pharmaceuticals filed its final 424B4 prospectus with the SEC on Oct. 9, 2026. Here is what the filing signals and what to check in the pricing terms.
Guide
Reading a 424B4 final prospectus: a section-by-section guide
What a 424B4 final prospectus is, when it is filed, and how to read its cover page, underwriting, dilution and use of proceeds sections, step by step.